German Building Stock News

XTRA:DB1
XTRA:DB1Capital Markets

Assessing Deutsche Börse (XTRA:DB1) Valuation After Mixed 2025 Earnings And Share Price Reaction

Deutsche Börse (XTRA:DB1) is back in focus after reporting fourth quarter and full year 2025 earnings, with higher sales alongside mixed net income trends that give investors fresh numbers to reassess the stock. See our latest analysis for Deutsche Börse. The earnings release appears to have shifted sentiment in the short term, with a 1-day share price return of 3.05% taking Deutsche Börse to €209.5. This comes even though the year-to-date share price return is a 4.29% decline and the 1-year...
XTRA:DOU
XTRA:DOUSpecialty Retail

Douglas (XTRA:DOU) Q1 EPS Slip Tests Bullish Margin Improvement Narrative

Douglas (XTRA:DOU) opened Q1 2026 with revenue of €1.7b and basic EPS of €1.34, following trailing twelve month revenue of €4.6b and EPS of €1.46. The company’s quarterly revenue increased from €1.65b in Q1 2025 to €1.7b in Q1 2026, while basic EPS moved from €1.51 to €1.34 over the same period, framing a quarter where profitability metrics will be scrutinised closely. With trailing net profit margins at 3.4% versus 2.7% a year earlier, this set of results puts the focus squarely on how...
XTRA:CBK
XTRA:CBKBanks

Assessing Commerzbank (XTRA:CBK) Valuation After Record 2025 Results And Higher Shareholder Returns

Commerzbank (XTRA:CBK) has drawn fresh attention after reporting a record operating result for 2025, committing about €2.7b to shareholders through a higher dividend and two share buybacks, alongside an upbeat 2026 outlook. See our latest analysis for Commerzbank. The record 2025 result, higher dividend and buyback plans arrive after a mixed year in the market, with a 30 day share price return of a 3.66% decline but a very large 5 year total shareholder return of more than 7x. This suggests...
XTRA:MRK
XTRA:MRKPharmaceuticals

Merck KGaA Electronics Leadership Shift And What It Means For Investors

Merck KGaA (XTRA:MRK) has appointed Benjamin Hein as chief executive of its Electronics business and member of the executive board. Hein succeeds Kai Beckmann, who has moved into the role of overall CEO of Merck KGaA. The leadership changes affect the group’s Electronics segment, a core supplier of materials for the semiconductor industry. The Electronics business sits at the heart of Merck KGaA’s role as a supplier to chipmakers, display manufacturers and other high tech end markets. For...
XTRA:1SXP
XTRA:1SXPLife Sciences

Schott Pharma KGaA (XTRA:1SXP) Margin Dip To 14.9% Tests Bullish Earnings Quality Narratives

Schott Pharma KGaA (XTRA:1SXP) has opened Q1 2026 with revenue of €240.2 million, basic EPS of €0.22 and net income of €33.2 million, setting a clear marker for how the new financial year is starting. Over the past year, the company has seen revenue move from €229.8 million in Q1 2025 to a trailing twelve month figure of €995.0 million, while basic EPS has tracked in a range between €0.19 and €0.30 quarterly, sitting at €0.99 on a trailing basis. This frames an earnings profile for investors...
XTRA:HNR1
XTRA:HNR1Insurance

Assessing Hannover Rück (XTRA:HNR1) Valuation After Upgraded 2026 Earnings Guidance

Why Hannover Rück’s upgraded 2026 guidance matters for shareholders Hannover Rück (XTRA:HNR1) confirmed earnings guidance for 2026, targeting Group net income of at least €2.7b, which is 12.5% above the previous year’s original forecast and is drawing fresh investor attention. See our latest analysis for Hannover Rück. The upgraded 2026 guidance has arrived as the share price has shown mixed momentum, with a 2.54% 1 day share price return and a 3.31% 30 day share price return contrasting with...
XTRA:NDX1
XTRA:NDX1Electrical

A Look At Nordex (XTRA:NDX1) Valuation After New European Wind Turbine Orders In Early 2026

Nordex (XTRA:NDX1) has kicked off 2026 with a series of new wind turbine orders across Europe, including projects in Sweden, the UK, Turkiye and Lithuania, adding several hundred megawatts of contracted capacity. See our latest analysis for Nordex. These new contracts arrive after a strong run for investors, with Nordex’s share price up 17.12% over the past 90 days and a very large 1 year total shareholder return of 176.74%, even though short term share price returns have softened in recent...
XTRA:MBG
XTRA:MBGAuto

Mercedes-Benz S-Class Refresh Tests AI Strategy And Margin Trade Offs

Mercedes-Benz Group (XTRA:MBG) has unveiled an extensively updated S-Class flagship sedan. The new model adds AI-driven infotainment and assistant features, along with advanced digital lighting and driver assistance systems. Mercedes-Benz is also introducing new hybrid and combustion engine options, with a focus on comfort and safety technology. For you as an investor, the S-Class matters because it often showcases the technologies that later spread across the broader Mercedes-Benz lineup...
XTRA:VOW3
XTRA:VOW3Auto

Is Volkswagen (XTRA:VOW3) Still Attractively Priced After Mixed 12‑Month Share Performance

If you are wondering whether Volkswagen at €103.55 is still offering value or if the easy money has already been made, you are not alone. The stock has been relatively mixed in the short term, with a 2.3% decline over the last week, a 1.0% gain over the last 30 days and a 17.7% return over the past year, while year to date it is down 2.7%. Recent coverage around Volkswagen has centered on its position in the global auto sector and investor interest in how legacy manufacturers are responding...
XTRA:DBK
XTRA:DBKCapital Markets

Deutsche Bank Green Bond Shows Funding Costs And ESG Demand In Focus

Deutsche Bank (XTRA:DBK) has issued its first EU standard green bond, raising €500 million. The proceeds are earmarked for refinancing assets in the bank’s green building portfolio. The deal follows an update to Deutsche Bank’s sustainable financing framework in Europe. For you as an investor, this move places Deutsche Bank’s core corporate and investment banking operations within the context of demand for labelled sustainable debt. The bank is tying part of its funding directly to assets...
XTRA:RWE
XTRA:RWERenewable Energy

RWE (XTRA:RWE) Valuation Check After Masdar Deal And New UK Clean Energy Contracts

RWE (XTRA:RWE) has been in focus after agreeing with Masdar to support energy security in Germany and Europe, while also securing contracts for difference for 290 MW of UK solar and onshore wind capacity. See our latest analysis for RWE. These expansion moves sit alongside a strong recent market run, with RWE’s share price at €54.24 and a 30 day share price return of 12.11% feeding into a 1 year total shareholder return of 96.99%. This suggests momentum has been building rather than...
XTRA:DHL
XTRA:DHLLogistics

Assessing Deutsche Post (XTRA:DHL) Valuation After Western Union Deal And Shareholder Payout Push

Why Deutsche Post is back on investors’ radar Deutsche Post (XTRA:DHL) has drawn fresh attention after announcing a partnership with Western Union for cross-border money transfers, alongside an ongoing share repurchase program and an announced annual dividend policy. See our latest analysis for Deutsche Post. The recent Western Union partnership and continued focus on shareholder returns have arrived during a period of firm momentum, with a 90-day share price return of 15.08% and a 1-year...
XTRA:FYB
XTRA:FYBBiotechs

February 2026's European Stocks Possibly Priced Below Estimated Value

As European markets continue to show resilience, with the pan-European STOXX Europe 600 Index reaching new highs and optimism about the eurozone economy bolstering investor sentiment, opportunities may arise for investors seeking stocks potentially priced below their estimated value. In this context, identifying undervalued stocks involves looking for companies that demonstrate strong fundamentals yet have not fully reflected these in their current market valuations amidst ongoing market...
XTRA:BAYN
XTRA:BAYNPharmaceuticals

Bayer Stroke Trial Success Puts Asundexian And Valuation In Focus

Bayer reported positive topline results from its pivotal Phase III OCEANIC-STROKE trial for asundexian, a Factor XIa inhibitor for secondary stroke prevention. The study showed a significant reduction in recurrent ischemic strokes versus placebo, without an increase in major bleeding events. The data mark the first successful Phase III readout for a Factor XIa inhibitor showing superiority to placebo in this setting, and follow Fast Track designation for asundexian from the FDA. Bayer,...
XTRA:ENR
XTRA:ENRElectrical

Siemens Energy (XTRA:ENR) TTM Margin Improvement Tests Premium 98.8x P/E Narrative

Siemens Energy (XTRA:ENR) has kicked off Q1 2026 following a period in which quarterly revenue increased from €8.9b in Q1 2025 to €10.4b in Q4 2025. Over the same stretch, basic EPS ranged from €0.23 to €0.71 before landing at €0.19 in the most recent quarter. Over the trailing twelve months to Q4 2025, the company’s revenue reached €39.1b with basic EPS of €1.63 and net income of €1.4b, setting up Q1 2026 against a backdrop of positive earnings and slightly higher reported margins. That...
DB:6DV0
DB:6DV0Real Estate

One Off Gain At Logistri Fastighets DB 6DV0 Challenges Bearish Profitability Narratives

Logistri Fastighets (DB:6DV0) has put fresh numbers on the table for FY 2025, reporting Q3 total revenue of SEK46.8 million alongside basic EPS of SEK0.48. Trailing 12-month figures show revenue of SEK168.6 million and EPS of SEK1.34, with earnings over the last year rising 11.1%. The company has reported an increase in revenue from SEK135.1 million to SEK168.6 million on a trailing 12-month basis, with EPS over that period moving from SEK0.88 to SEK1.34. Results were affected by a one-off...